In summary, we found that PI3Kα-selective inhibitor CYH33 displayed potent activity against HNSCC, which was associated with inhibition of Akt signaling as well as attenuation of PI3K-dependent GAB1/Erk phosphorylation. This evidence concerns the gene MAPK1 and head and neck squamous cell carcinoma.